期刊
MINI-REVIEWS IN MEDICINAL CHEMISTRY
卷 4, 期 3, 页码 255-271出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389557043487394
关键词
FLT3; tyrosine kinase; kinase inhibitor; AML; KIT; PDGFR
Activating mutations of the FLT3 receptor tyrosine kinase are the most common recurring genetic abnormality in acute myelogenous leukemia (AM). Inhibition of FLT3 kinase activity by small molecule inhibitors has been proposed as a novel therapeutic approach AML. The pre-clinical and clinical development of candidate FLT3 inhibitors will be reviewed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据